Caribou Biosciences

Edit info

Founded: 2012

Location: Berkeley, CA

Employee range: 50 - 200

Clinical stage: Clin1

Therapy area: B-cell NHL

Drug types: ONC

Lead product: CB-010

Funding: $25M stock Jul 2023; $304M IPO Jul 2021; $115M C Mar 2021; $30M B May 2016; $11M A Apr 2015

cariboubio.com

linkedin.com

job board

Drug notes:

CB-011 Clin1 multiple myeloma; CB-012 Clin0 AML; CB-020 RD solid tumors; 2 undisclosed programs RD undisclosed

About:

Caribou Biosciences is developing CRISPR technologies to create allogeneic cell therapies for oncology. Caribou has built CRISPR hybrid RNA-DNA (chRDNA), their proprietary technology that enables highly efficient, highly specific genome editing. chRDNA is then used to develop sophisticated genome-edited cell therapies. For example, Caribou is using chRDNA to create next-generation allogeneic CAR-T and CAR-NK cell therapies to enhance the longevity and persistence of the cells. Scientific advances have been published in high-impact journals. Caribou has one ongoing Phase I clinical trial to evaluate CB-010 in adults with relapsed B cell non-Hodgkin lymphoma.